(Q38633337)

5 September 2017

title

Tau-imaging in neurodegeneration (English)

1 reference

5 September 2017

1 reference

4

Alexander Drzezga

0 references

author name string

Gérard N Bischof

series ordinal

1

1 reference

5 September 2017

Heike Endepols

series ordinal

2

1 reference

5 September 2017

Thilo van Eimeren

series ordinal

3

1 reference

5 September 2017

publication date

5 August 2017

1 reference

5 September 2017

1 reference

Frequency of stages of Alzheimer-related lesions in different age categories

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Merck ends trial of potential Alzheimer's drug verubecestat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Staging of Alzheimer's disease-related neurofibrillary changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Neurodegenerative tauopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

7 January 2021

Frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Variation in tau isoform expression in different brain regions and disease states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau in physiology and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Aβ-amyloid and Tau Imaging in Dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Anti-tau antibodies: hitting the target.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Towards a Pharmacophore for Amyloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Atomic structures of amyloid cross-beta spines reveal varied steric zippers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Research towards tau imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

QSAR studies for prediction of cross-β sheet aggregate binding affinity and selectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Ligand polarizability contributes to tau fibril binding affinity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau imaging in neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau positron emission tomographic imaging in aging and early Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau PET imaging: present and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

In vivo tau imaging: obstacles and progress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Synthesis and quality control of [(18) F]T807 for tau PET imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Development of [11C]/[3H]THK-5351 - A potential novel carbon-11 tau imaging PET radioligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Synthesis of a PET tau tracer [(11)C]PBB3 for imaging of Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

18F-Labeled 2-Arylquinoline Derivatives for Tau Imaging: Chemical, Radiochemical, Biological and Clinical Features.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Preclinical Evaluation of 18F-JNJ64349311, a Novel PET Tracer for Tau Imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

An autoradiographic evaluation of AV-1451 Tau PET in dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Characteristics of Tau and Its Ligands in PET Imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

PET Quantification of Tau Pathology in Human Brain with 11C-PBB3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Advances in the development of tau PET radiotracers and their clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Animal models of Alzheimer's disease and frontotemporal dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Neuropathological assessment and validation of mouse models for Alzheimer's disease: applying NIA-AA guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau suppression in a neurodegenerative mouse model improves memory function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

PET Imaging of Tau Deposition in the Aging Human Brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

[F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

PART is part of Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

TAU-PET PATTERNS OVERLAP AND EXCEED HYPOMETABOLISM IN ALZHEIMER'S DISEASE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

[18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Dementia with Lewy bodies from the perspective of tauopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Human Radiation Dosimetry of [(18)F]AV-1451(T807) to Detect Tau Pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Biodistribution and Radiation Dosimetry for the Tau Tracer 18F-THK-5351 in Healthy Human Subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Identification of a major radiometabolite of [11C]PBB3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

A new method to quantify tau pathologies with (11)C-PBB3 PET using reference tissue voxels extracted from brain cortical gray matter.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

[18F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2017.08.003

10.1016/J.YMETH.2017.08.003

7 January 2021

Identifiers

DOI

1 reference

5 September 2017

1 reference